B lymphocytes originate from pluripotent hematopoietic stem cells and differentiate into antibody-secreting cells through multistep differentiation stages, such as pre-B cells, immature B cells with surface IgM, and mature B cells with surface IgM and IgD . A number of human B cell antigens have been defined by in Abs (I-10) . However, most B cell-specific mAbs, except for antibodies against plasma cells (5) and activated B cells (9, 10) , are known to recognize cells of the B lineage at a wide range of differentiation stages from pre-B cells to mature B cells . It has therefore been difficult to identify B cells at a specific differentiation stage by using such B cell-specific mAbs.
incubated with FITC-conjugated or biotinylated antibodies for 20 min in a flexible 96-well microtiter plate in the first step, washed three times with staining buffer, then incubated with Texas red (TR)-avidin for 20 min in the second step and washed three times with staining buffer . Propidium iodide (PI) (10 wg/ml) was included in the last 5 min of the second step to label dead cells . All antibodies except for biotinylated human IgG and IgE were used at the concentrations that gave maximal fluorescence intensities without nonspecific binding. Biotinylated human IgE and IgG were used at 300 Ag/ml because of low binding affinity of the receptors on lymphocytes, moreover, this concentration could not saturate Fcy and Fce receptors . Stained cells were analyzed on a FACS 440 equiped with both argon ion laser operating at 488 nm generating forward scatter, fluorescein, PI, and large-angle (obtuse) scatter signals, and a second argon laser pumping an orange dye laser circulating rhodamine 6G tuned to emit 595-nm light to excite TR (25) . All fluorescein channels and large-angle scatter were amplified logarithmically with a range of either four decade (for fluorescence) or two decade (obtuse scatter) . List-mode data were collected on 20-50 X 10' cells for each sample and analyzed on a Vax 11/730 computer using programs originally developed at Stanford University. Histograms represent the relative number ofcells as a function offluorescence intensity within a particular gated population. Contour plots represent the correlated expression of two surface antigens by showing peak lines enclosing equal percentages ofcells with the two-parameters distribution .
Induction of FCeR Expression . Bone marrow MNC, sorted cells, or PBL from a patient with CVI were cultured at 5 X 105 cells/ml in a 96-well microtiter plate for 3 d in the presence or absence of 10 jAg/ml IgE or IgG with or without PHA supernatant (10% vol/vol) or recombinant or purified lymphokines . After 3 d of culture, the cells were stained with FITC-anti-B1 and biotinylated anti-FceR antibodies, followed by incubation with TR-avidin, and analyzed by FACS.
Results
Expression of FceR on Human B Lymphocytes from PBL, Tonsils, and Bone Marrow . Anti-FceR mAbs 1-7 (1'2b), 3-5 ('Y,), and 8-30 (A), have been prepared by using RPMI-8866 cells as immunizing antigen . In an earlier study (15) , it was shown that two mAbs (1-7 and 8-30) recognized the same epitope of FceR and inhibited the binding of IgE with 8866 cells, while mAb 3-5 recognized a different epitope of FceR and did not inhibit the IgE binding . However, all these mAbs could precipitate 25,000 and 46,000 M, polypeptides under reducing and non-reducing conditions (15) . By using these mAbs, the distribution of FceR+ cells in various lymphoid tissues, such as PBL, tonsils, and bone marrow, was examined . Because the three mAbs showed the same results, mAb 8-30 was used in all the experiments. MNC from various lymphoid tissues were stained with FITC-anti-B1 and biotinylated anti-FceR followed by TR-avidin and analyzed by dual-laser FACS . As described in Table I , FceR was expressed on most Bl + B cells in PBL, and approximately one-half of B1 + B cells derived from tonsils. On the other hand, only a small fraction of B1 + B cells were positive for the FceR expression in bone marrow . It is noteworthy that B1 -cells did not express FceR in any of the lymphoid tissues tested . The variability in the frequency of FceR+ cells in PBL, tonsils, and bone marrow suggests that FceR may be expressed on B cells at a certain defined differentiation or activation stage .
Correlation of FceR Expression and Ig Isotypes on B Cells. Tonsillar MNC were stained with anti-FceR and with conjugates directed against different Ig isotypes. As shown in Fig . 1 A, FceR was expressed on most A and S positive B cells in tonsils . On the other hand, almost all -y-or a-bearing B cells, which were Because of the paucity of E-bearing B cells in PBL or tonsils, the expression of FcER on E+ B cells could not be examined . Therefore, PBL from patients with hyper-IgE syndrome were studied. Fig. 3 shows the representative results observed in PBL from two patients with hyper-IgE syndrome . In fact, the FcER expression was augmented in A, + or S+ B cells in these patients compared to that in normal individuals (Fig . 3, A Induction of FLER in Bone Marrow and Tonsillar B Cells. As described in Table  I , p .+,5+ B cells in PBL were FcER +, while B cells in bone marrow were FcER-, suggesting that only circulating mature B cells are able to express FcER . Moreover, experiments were conducted to study whether FccR could be induced in bone marrow B cells by certain factors. As shown in Fig. 4 , T cell-derived PHAconditioned medium (PHA-sup) could induce the FccR expression on 131' B cells (Fig . 4 A) , particularly on S+ B cells (Fig . 4 B) . The addition of IgE but not IgG could augment the PHA-sup-induced expression of FcER . However, IgE alone, without PHA-sup, showed no effect on FcER expression .
As described earlier, circulating 6-B cells, which are mainly a' or y+ , do not Lymphokine(s) Responsible for FcER Expression . To examine the nature of Lmphokine(s) responsible for the induction of FcER, bone marrow MNC were cultured with recombinant or highly purified lymphokines in the presence of IgE. As shown in Fig. 6 , none of the recombinant or purified lymphokines, including IL-1 (Fig . 6 B) , IL-2 (C), IFN-,Q (D), IFN-y (E), and BCDF (F) and crude B-BCGF (Fig . 6 G) induced the expression of FCER . A mixture of these lymphokines (Fig . 6 H) also failed to induce the FCER expression . On the other hand, PHA-sup (Fig . 61) could induce the FcER expression in more than half of the bone marrow B cells. As shown (Fig . 6j) , IFN-y almost completely abrogated Fluorescence intensity and two cases of AT were studied, and the results are summarized in Table II . In all these cases, most of the B cells expressed both IgM and IgD, although some patients had few B cells . It was interesting to note that >90% of Bl + B cells in all these patients did not express FceR . The results suggest that B cells from these patients are similar in their differentiation stage to /, +,5 + B cells found in the bone marrow rather than in PBL. The results furthermore suggest a possible arrest in the maturation of these B cells. To study whether FcER could be induced by external signals, PBL from a patient with CVI (CVI-1) were cultured with PHA-sup and IgE for 3 d, and the FcER expression on B1 + B cells was examined . As shown in Fig. 7 B, PHA-sup could induce FcER expression in a certain fraction of those B cells, and the addition of IgE could augment the expression (Fig . 7 C) , suggesting that those B cells are in a similar differentiation stage as that of bone marrow B cells. These results show that the majority of circulating u+b+ B cells express FcER, and this is in marked contrast with several previous studies (11) (12) (13) (14) in which it was reported that only a few percent of Fc(-R+ cells were detected in PBL by the rosette method with IgE-conjugated ORBC . The discrepancy may be due to the difference in sensitivity between the assay systems used . It is important to note that the FcER found on the surface of lymphocytes are of relatively low affinity compared with the homologous receptors on mast cells and basophils (30) , and therefore the use of highly specific mAbs has helped in monitoring the expression of FCER . In the present study, the expression of FcER was restricted to B1 + cells even after induction. This is in marked contrast with previously reported studies (13, 26) . Therefore, the specificity of the mAbs, used should be confirmed. The specificity of the anti-FcER antibodies has been extensively studied in our previous report (15) The results obtained with biotinylated IgE were also identical with those observed with the mAbs . In the staining with biotinylated IgE, >300 Ag/ml IgE could not saturate the receptors. Therefore, the present results indicate that the lymphocyte FCER with low affinity is a B cell-specific differentiation marker . The discrepancy between our and several other results (11) (12) (13) (14) 26) cannot be explained at the present time .
A number of B cell-specific mAbs have been reported . However, surface molecules recognized with most of these antibodies are expressed on B-lineage cells in a wide range of differentiation stages, including immature bone marrow and mature B cells. None of the mAbs so far reported could differentiate bone marrow B cells and circulating B cells, as demonstrated using anti-FcER and presented in this study. Some of the earlier reported antibodies, however, could react only with activated B cells (9, 10) , B blasts (31, 32) The expression of FCER was inducible in bone marrow B cells with PHA-sup. However, recombinant IL-2, IL-1, IFN-y, IFN-a, and purified BCDF did not show any effect on the expression of FcER . PHA-sup used herein probably contains BSF-1-like activity, since it showed a strong synergy with anti-Fe for the proliferation of Ba -resting B cells (33) . Therefore, a possible candidate responsible for the FCER induction may be BSF-1 (34, 35) . Furthermore, the observation that IFN-y could completely inhibit the FCER expression induced by PHA-sup strongly suggests that the human counterpart of BSF-1 may be responsible for FCER induction, since IFN-y is known to inhibit the effect of BSF-1 in the activation of murine resting B cells (29) .
The 
Summary
The expression of FcER on human lymphocytes was studied with the anti-FcER mAbs . FCER was expressed on most A.+,b + circulating B cells, whereas T cells did not express FcER even in patients with hyper-IgE syndrome . B cells with y, a, or E phenotype did not express FcER, moreover its expression could not be induced, suggesting that the FCER expression was correlated with isotype switching. A,+b+ B cells in bone marrow did not express FcER, but PHA-sup (supernatant from PHA-stimulated cell cultures) could induce its expression, and the addition of IgE augmented this induction. Recombinant IL-2, IL-1, IFN-y or -0, or purified B cell differentiation factor (BSF-2 B cell-stimulatory factor 2) could not induce FceR expression in bone marrow B cells. IFN-y inhibited the FcER expression induced by PHA-sup, suggesting that the human counterpart of BSF-I may be responsible for FccR expression in bone marrow B cells. B cells from patients with common variable immunodeficiency and ataxia teleangiectasia did not express FccR, but PHA-sup could induce its expression, indicating that circulating B cells of these patients are at a differentiation stage similar to B cells in bone marrow . The study showed that FccR is a B cell-specific differentiation marker, the expression of which is restricted to a defined stage of B cell differentiation.
Receivedfor publication 22 April 1986 and in revised form 10June 1986. Note added in proof. Recent experiments with the newly cloned BSF-1 (IL-4) (Proc. Nad. Acad. Sci. USA. 83 :5894. 1986 ) and kindly provided by DNAX Corp ., revealed that this lymphokine could induce the expression of FceR on human bone marrow B cells, confirming our observations made earlier in this study.
